FDA’s Ganley Puts Rx Switch Studies In “Real World” Context

Accurate extrapolation of actual-use data into broader consumer settings will be a defining measure of success for switching chronic disease drugs in the future, according to FDA Office of Nonprescription Products Director Charles Ganley, MD